Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp AZD4547 lung large cell carcinoma sensitive detail...
FGFR1 positive AZD4547 + AZD8055 lung large cell carcinoma sensitive detail...
FGFR1 positive AZD4547 + Vistusertib lung large cell carcinoma sensitive detail...
FGFR1 positive AZD4547 + Sirolimus lung large cell carcinoma sensitive detail...
TP53 R175L NSC319726 lung large cell carcinoma sensitive detail...
TP53 wild-type NSC319726 lung large cell carcinoma resistant detail...
FGFR1 amp ODM-203 lung large cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02185690 Phase I Binimetinib + Carboplatin + Pemetrexed Disodium A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung Completed CAN 0
NCT03591731 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) Active, not recruiting FRA 0
NCT03976518 Phase II Atezolizumab Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE) Recruiting ITA 0
NCT04748419 Phase Ib/II Durvalumab Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab Recruiting USA 0
NCT05198830 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + TRC102 Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer Recruiting USA 0